Nucleus® smart sound processing technology
Whether you’re in a restaurant, classroom or office, our latest Nucleus sound processors are designed to help you hear your best.
What you'll find on this page
- How our hearing technology adapts to your listening environment.
- Hear speech more clearly in noise with ForwardFocus technology.
Experience your best hearing
Inspired by connecting you with your world, we’re driven to innovate and deliver hearing technology to help you hear your best, no matter where you are or where the day takes you.
Our sound processors feature technology that's designed to help you hear conversations clearly, particularly in noise. Whether you're walking in the park on a windy day, sitting in a work meeting or classroom, or chatting to friends in a noisy cafe, our advanced hearing technology automatically adjusts to give you the best possible listening settings.1-4
Our latest behind-the-ear sound processor, the Nucleus 8, features enhanced SmartSound IQ 2 with SCAN 2 technology* that senses changes in your listening environment and automatically adjusts to deliver clear sound.1-3
Focus on what’s important
Feel part of every conversation and immerse yourself in each moment. With ForwardFocus†, our latest sound processors reduce unwanted noise from behind you, so you can hear face-to-face conversations more clearly.
Featuring enhanced ForwardFocus, the Nucleus® 8 Sound Processor is designed to more powerfully reduce background noise and can be user controlled or automated to help you focus on what's important in any situation.5,#
"With the Cochlear implant I don't have a problem understanding my family, my wife and my daughter."
- Mathias, Cochlear™ Nucleus® recipient
More information
Disclaimer
Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.
For a full list of Cochlear’s trademarks, please visit our Terms of Use page.
In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss.
In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss.
In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 10 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk.
For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.
Any testimonial featured on this website is intended for an Australian audience only.
† ForwardFocus is a clinician-enabled feature that can be user-controlled or automated.
* Compared to Nucleus 6 and Nucleus 7 sound processors.
# Compared to Nucleus® 7 Sound Processor with ForwardFocus on.
For information regarding the compatibility of Cochlear's Sound Processors with Apple or Android devices, visit www.cochlear.com/compatibility
Android is a trademark of Google LLC.
References
- Mauger SJ, et al. Clinical outcomes with the Kanso off-the-ear cochlear implant sound processor. Int J Audiol. (2017 Apr); 56(4): 267-276. [Sponsored by Cochlear].
- Mauger SJ, et al. Clinical evaluation of the Nucleus 6 cochlear implant system: performance improvements with SmartSound iQ. Int J Audiol. (2014 Aug); 53(8): 564-576. [Sponsored by Cochlear]
- Wolfe J, et al. Benefits of Adaptive Signal Processing in a Commercially Available Cochlear Implant Sound Processor. Otol Neurotol. (2015 Aug);36(7):1181-90.
- Cochlear Limited D1864200 SCAN-X Design Description.
- Cochlear Limited. D1964109 Clinical Investigation Report CLTD5804 (2022 Feb).